Chiba-Based GeneFrontier Enters Drug Discovery Field
This article was originally published in PharmAsia News
Chiba-based biopharmaceutical company GeneFrontier announced it will utilize antibody technology and enter the drug discovery business. The company plans to obtain proteins that were discovered by university research centers and will make antibodies based on the proteins, then license the protein and antibody set products to pharmaceutical companies. Currently, the company has one such project under way, and plans to license it to drug companies within the year. The company aims to conduct four projects and commercialize one to two products annually. (Click here for more - Japanese language
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.